BAYRY BAYER AG S/ADR Loading...

From TMO earnings calls
Loading chart...
Top Calls
Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
08:30
Jan 29 ◎
Mark Casper Chairman, President, and CEO, Thermo Fisher Scientific Inc TMO Q4 FY25 call
Thermo Fisher's Oncomind DX test was FDA-approved as a companion diagnostic for Bayer's therapy, strengthening Bayer's targeted lung cancer treatment and driving demand for Thermo Fisher's NGS diagnostics.
BAYRY
HIGH

About BAYRY Analyst Coverage

Buzzberg tracks BAYRY (BAYER AG S/ADR) across 1 sources. 0 bullish vs 0 bearish calls from 1 analysts. Sentiment: evenly split. 1 total trade idea tracked. Latest voices: Mark Casper.